NCT02417701View on ClinicalTrials.gov

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions
Recurrent Lung Squamous Cell CarcinomaStage IV Lung Squamous Cell Carcinoma AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sapanisertib

Given PO

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02417701 - Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | Biotech Hunter | Biotech Hunter